Verrica Pharmaceuticals Inc.

NASDAQ:VRCA

Biotechnology

Healthcare
$3.14 -0.26%

-$0.02 today

Market cap
$53.94M
Beta
1.49
P/E (TTM)
-3.5
EPS (TTM)
-$1.67
52W Low $3.28High $9.82

Volume 0.10M

Average 0.08M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$17.63M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$1.45M

FY 2025 · Annual

-96.2% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.08M)(24.49M)(67M)(76.58M)(17.89M)
Depreciation & Amortization472K718K836K1.27M429K
Deferred Income Tax66K0000
Stock-Based Compensation6.05M4.99M14.38M7.16M3.32M
Change in Working Capital(535K)(1.8M)9.86M2.03M(6.25M)
Accounts Receivables0(487K)(3.93M)4.34M(5.32M)
Inventory0487K000
Accounts Payables497K(338K)2.2M(568K)176K
Other Working Capital(1.03M)(1.46M)11.59M(1.74M)(1.11M)
Other Non-Cash Items1.44M1.93M3.35M5.19M2.76M
Operating Cash Flow(27.58M)(18.65M)(38.58M)(60.93M)(17.63M)
Capital Expenditures(883K)(302K)(362K)(27K)0
Acquisitions (Net)00000
Purchases of Investments(68.91M)(4.49M)000
Sales of Investments69M59.01M000
Other Investing Activities(201K)(180K)08K0
Investing Cash Flow(998K)54.04M(362K)(19K)0
Debt Repayment4.97M(43.75M)44.08M(2.06M)(48.2M)
Common Stock Issued28.12M26.9M30.3M39.64M50.07M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities558K(17K)(169K)155K(420K)
Financing Cash Flow33.65M(16.87M)74.21M37.73M1.45M
Effect of Forex Changes00000
Net Change in Cash5.07M18.52M35.27M(23.22M)(16.18M)
Free Cash Flow(28.47M)(18.95M)(38.94M)(60.95M)(17.63M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$17.9M
+ D&A$429.0K
+ Stock-Based Comp$3.3M
+ Deferred Tax$0
- Working Capital-$6.3M
+ Other Non-Cash$2.8M
= Operating Cash Flow-$17.6M
- Capex$0
= Free Cash Flow-$17.6M

Analysis

FY2025 free cash flow is -$17.6M. FCF conversion is 98.6% of net income. Operating cash flow was -$17.6M, with capex of $0. The largest bridge item is Working Capital at -$6.3M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 13, 2026
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 12, 2026
4Statement of changes in beneficial ownershipAug 18, 2026
4Statement of changes in beneficial ownershipAug 18, 2026

Does VRCA generate free cash flow?

Verrica Pharmaceuticals Inc. (VRCA) generated -$17.63M of free cash flow in fiscal 2025.

How much operating cash flow does VRCA produce?

Operating cash flow was -$17.63M, before capital expenditures of $0.00.